Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets

References

• Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–1170.
   PubMed Web of Science ®Google Scholar
• Sirpal S, Chandok N. Primary sclerosing cholangitis: diagnostic and management challenges. Clin Exp Gastroenterol. 2017;10:265–273.
   PubMed Web of Science ®Google Scholar
• Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391:2547–2559.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298–1323.
   PubMed Web of Science ®Google Scholar
• Taghavi SA, Eshraghian A, Niknam R, et al. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2018;12:575–584.
   PubMed Web of Science ®Google Scholar
• Lleo A, Marzorati S, Anaya JM, et al. Primary biliary cholangitis: a comprehensive overview. Hepatol Int. 2017;11:485–499.
   PubMed Web of Science ®Google Scholar
• Tsuneyama K, Baba H, Morimoto Y, et al. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Invest. 2017;64:7–13.
   PubMed Web of Science ®Google Scholar
• Gulamhusein AF, Hirschfield GM. Pathophysiology of primary biliary cholangitis. Best Pract Res Clin Gastroenterol. 2018;34–35:17–25.
   PubMed Web of Science ®Google Scholar
• Lakshminarayanan B, Davenport M. Biliary atresia: a comprehensive review. J Autoimmun. 2016;73:1–9.
   PubMed Web of Science ®Google Scholar
• Nizery L, Chardot C, Sissaoui S, et al. Biliary atresia: clinical advances and perspectives. Clin Res Hepatol Gastroenterol. 2016;40:281–287.
   PubMed Web of Science ®Google Scholar
• Govindarajan KK. Biliary atresia: where do we stand now? World J Hepatol. 2016;8:1593–1601.
   PubMed Web of Science ®Google Scholar
• Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol. 2013;304:G449–G468.
   PubMed Web of Science ®Google Scholar
• Fickert P, Pollheimer MJ, Beuers U, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol. 2014;60:1290–1303.
   PubMed Web of Science ®Google Scholar
• Pollheimer MJ, Fickert P. Animal models in primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol. 2015;48:207–217.
   PubMed Web of Science ®Google Scholar
• McMillin M, Frampton G, Grant S, et al. The neuropeptide galanin is up-regulated during cholestasis and contributes to cholangiocyte proliferation. Am J Pathol. 2017;187:819–830.
   PubMed Web of Science ®Google Scholar
• Tag CG, Sauer-Lehnen S, Weiskirchen S, et al. Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp. 2015;96:e52438.
   Google Scholar
• Alpini G, Ulrich CD 2nd, Phillips JO, et al. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. A J Physiol. 1994;266:G922–G928.
   PubMedGoogle Scholar
• Fickert P, Stoger U, Fuchsbichler A, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol. 2007;171:525–536.
   PubMed Web of Science ®Google Scholar
• Raven A, Lu WY, Man TY, et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature. 2017;547:350–354.
   PubMed Web of Science ®Google Scholar
• Sato K, Marzioni M, Meng F, et al. Ductular reaction in liver diseases: pathological mechanisms and translational significances. Hepatology. 2019;69:420–430.
   PubMed Web of Science ®Google Scholar
• Delire B, Starkel P, Leclercq I. Animal models for fibrotic liver diseases: what we have, what we need, and what is under development. J Clin Transl Hepatol. 2015;3:53–66.
   PubMed Web of Science ®Google Scholar
• De Minicis S, Kisseleva T, Francis H, et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis. 2013;45:450–459.
   PubMedGoogle Scholar
• Wang H, Zhang H, Zhang Z, et al. Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci Rep. 2016;6:19445.
   PubMed Web of Science ®Google Scholar
• LeSage GD, Benedetti A, Glaser S, et al. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology. 1999;29:307–319.
   PubMed Web of Science ®Google Scholar
• Fujii T, Fuchs BC, Yamada S, et al. Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010;10:79.
   PubMed Web of Science ®Google Scholar
• Bansal R, Frelin L, Brenndorfer ED, et al. Hepatitis C virus nonstructural 3/4A protein dampens inflammation and contributes to slow fibrosis progression during chronic fibrosis in vivo. PLoS One. 2015;10:e0128466.
   PubMed Web of Science ®Google Scholar
• Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 1994;145:1237–1245.
   PubMed Web of Science ®Google Scholar
• Wu N, Meng F, Zhou T, et al. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. FASEB J. 2017;31:4305–4324.
   PubMed Web of Science ®Google Scholar
• Petrescu AD, Grant S, Frampton G, et al. Glucocorticoids cause gender-dependent reversal of hepatic fibrosis in the MDR2-knockout mouse model. Int J Mol Sci. 2017;18:2389.
   Web of Science ®Google Scholar
• Jones H, Hargrove L, Kennedy L, et al. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2-/- mice. Hepatology. 2016;64:1202–1216.
   PubMed Web of Science ®Google Scholar
• Moncsek A, Al-Suraih MS, Trussoni CE, et al. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/-) mice. Hepatology. 2018;67:247–259.
   PubMed Web of Science ®Google Scholar
• Fiorotto R, Villani A, Kourtidis A, et al. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology. 2016;64:2118–2134.
   PubMed Web of Science ®Google Scholar
• Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet. 2003;113:286–292.
   PubMed Web of Science ®Google Scholar
• Werlin S, Scotet V, Uguen K, et al. Primary sclerosing cholangitis is associated with abnormalities in CFTR. J Cyst Fibros. 2018;17:666–671.
   PubMed Web of Science ®Google Scholar
• Martin CR, Zaman MM, Ketwaroo GA, et al. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol. 2012;303:G474–G481.
   PubMed Web of Science ®Google Scholar
• Debray D, El Mourabit H, Merabtene F, et al. Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice. Hepatol Commun. 2018;2:1533–1549.
   PubMed Web of Science ®Google Scholar
• Gossard AA, Lindor KD. Hepatocellular carcinoma: low risk of HCC in patients who have PSC and cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11:276–277.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A. 2014;111:1090–1095.
   PubMed Web of Science ®Google Scholar
• Harada K, Sato Y, Ikeda H, et al. Epithelial-mesenchymal transition induced by biliary innate immunity contributes to the sclerosing cholangiopathy of biliary atresia. J Pathol. 2009;217:654–664.
   PubMed Web of Science ®Google Scholar
• Robertson H, Kirby JA, Yip WW, et al. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology. 2007;45:977–981.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 2007;282:23337–23347.
   PubMed Web of Science ®Google Scholar
• Sato Y, Harada K, Ozaki S, et al. Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol. 2007;171:1859–1871.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196.
   PubMed Web of Science ®Google Scholar
• Zhao YL, Zhu RT, Sun YL. Epithelial-mesenchymal transition in liver fibrosis. Biomed Rep. 2016;4:269–274.
   PubMed Web of Science ®Google Scholar
• Taura K, Iwaisako K, Hatano E, et al. Controversies over the epithelial-to-mesenchymal transition in liver fibrosis. J Clin Med. 2016;5:9.
   Web of Science ®Google Scholar
• Chu AS, Diaz R, Hui JJ, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology. 2011;53:1685–1695.
   PubMed Web of Science ®Google Scholar
• Scholten D, Osterreicher CH, Scholten A, et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology. 2010;139:987–998.
   PubMed Web of Science ®Google Scholar
• Hatano R, Akiyama K, Tamura A, et al. Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice. Hepatology. 2015;61:1660–1671.
   PubMed Web of Science ®Google Scholar
• Tamura A, Kikuchi S, Hata M, et al. Achlorhydria by ezrin knockdown: defects in the formation/expansion of apical canaliculi in gastric parietal cells. J Cell Biol. 2005;169:21–28.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O‘Hara SP, Splinter PL, et al. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology. 2014;59:2263–2275.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Trussoni CE, O‘Hara SP, et al. Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab Invest. 2014;94:1126–1133.
   PubMed Web of Science ®Google Scholar
• Loarca L, De Assuncao TM, Jalan-Sakrikar N, et al. Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. Lab Invest. 2017;97:1385–1396.
   PubMed Web of Science ®Google Scholar
• Dianat N, Dubois-Pot-Schneider H, Steichen C, et al. Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepatology. 2014;60:700–714.
   PubMed Web of Science ®Google Scholar
• Sampaziotis F, de Brito MC, Madrigal P, et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol. 2015;33:845–852.
   PubMed Web of Science ®Google Scholar
• Reshetnyak VI. Primary biliary cirrhosis: clinical and laboratory criteria for its diagnosis. World J Gastroenterol. 2015;21:7683–7708.
   PubMed Web of Science ®Google Scholar
• Koarada S, Wu Y, Fertig N, et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol. 2004;173:2315–2323.
   PubMed Web of Science ®Google Scholar
• Irie J, Wu Y, Wicker LS, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med. 2006;203:1209–1219.
   PubMed Web of Science ®Google Scholar
• Nakagome Y, Ueno Y, Kogure T, et al. Autoimmune cholangitis in NOD.c3c4 mice is associated with cholangiocyte-specific Fas antigen deficiency. J Autoimmun. 2007;29:20–29.
   PubMed Web of Science ®Google Scholar
• Schrumpf E, Jiang X, Zeissig S, et al. The role of natural killer T cells in a mouse model with spontaneous bile duct inflammation. Physiol Rep. 2017;5:e13117.
   Web of Science ®Google Scholar
• Schrumpf E, Kummen M, Valestrand L, et al. The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol. 2017;66:382–389.
   PubMed Web of Science ®Google Scholar
• Huang W, Rainbow DB, Wu Y, et al. A novel Pkhd1 mutation interacts with the nonobese diabetic genetic background to cause autoimmune cholangitis. J Immunol. 2018;200:147–162.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171–181.
   PubMed Web of Science ®Google Scholar
• Oertelt S, Lian ZX, Cheng CM, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol. 2006;177:1655–1660.
   PubMed Web of Science ®Google Scholar
• Ma HD, Zhao ZB, Ma WT, et al. Gut microbiota translocation promotes autoimmune cholangitis. J Autoimmun. 2018;95:47–57.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang R, Zhang J, et al. Proteomic analysis reveals distinctive protein profiles involved in CD8(+) T cell-mediated murine autoimmune cholangitis. Cell Mol Immunol. 2018;15:756–767.
   PubMed Web of Science ®Google Scholar
• Medina JF, Martinez A, Vazquez JJ, et al. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 1997;25:12–17.
   PubMed Web of Science ®Google Scholar
• Salas JT, Banales JM, Sarvide S, et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134:1482–1493.
   PubMed Web of Science ®Google Scholar
• Medina JF, Recalde S, Prieto J, et al. Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci U S A. 2003;100:15847–15852.
   PubMed Web of Science ®Google Scholar
• Funauchi M, Sugishima H, Minoda M, et al. Serum level of interferon-gamma in autoimmune diseases. Tohoku J Exp Med. 1991;164:259–267.
   PubMed Web of Science ®Google Scholar
• Pollard KM, Cauvi DM, Toomey CB, et al. Interferon-gamma and systemic autoimmunity. Discov Med. 2013;16:123–131.
   PubMed Web of Science ®Google Scholar
• Hodge DL, Berthet C, Coppola V, et al. IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. J Autoimmun. 2014;53:33–45.
   PubMed Web of Science ®Google Scholar
• Bae HR, Leung PS, Tsuneyama K, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology. 2016;64:1189–1201.
   PubMed Web of Science ®Google Scholar
• Bae HR, Hodge DL, Yang GX, et al. The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity. Hepatology. 2018;67:1408–1419.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Lian ZX, Leung PS, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology. 2008;48:531–540.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Yang YH, Tsuneyama K, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011;53:915–925.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Yoshida K, Leung PS, et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol. 2009;155:577–586.
   PubMed Web of Science ®Google Scholar
• Hsueh YH, Chen HW, Syu BJ, et al. Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis. J Autoimmun. 2018;95:159–170.
   PubMed Web of Science ®Google Scholar
• Okada C, Akbar SM, Horiike N, et al. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int. 2005;25:595–603.
   PubMed Web of Science ®Google Scholar
• Jiang T, Han Z, Chen S, et al. Resistance to activation-induced cell death and elevated FLIPL expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model. Clin Exp Med. 2009;9:269–276.
   PubMed Web of Science ®Google Scholar
• Garrido M, Escobar C, Zamora C, et al. Bile duct ligature in young rats: a revisited animal model for biliary atresia. Eur J Histochem. 2017;61:2803.
   PubMed Web of Science ®Google Scholar
• Averbukh LD, Wu GY. Evidence for viral induction of biliary atresia: a review. J Clin Transl Hepatol. 2018;6:410–419.
   PubMed Web of Science ®Google Scholar
• Allen SR, Jafri M, Donnelly B, et al. Effect of rotavirus strain on the murine model of biliary atresia. J Virol. 2007;81:1671–1679.
   PubMed Web of Science ®Google Scholar
• Mao Y, Tang S, Yang L, et al. Inhibition of the Notch signaling pathway reduces the differentiation of hepatic progenitor cells into cholangiocytes in biliary atresia. Cell Physiol Biochem. 2018;49:1074–1082.
   PubMed Web of Science ®Google Scholar
• Shivakumar P, Campbell KM, Sabla GE, et al. Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia. J Clin Invest. 2004;114:322–329.
   PubMed Web of Science ®Google Scholar
• Jee J, Mourya R, Shivakumar P, et al. Cxcr2 signaling and the microbiome suppress inflammation, bile duct injury, and the phenotype of experimental biliary atresia. PLoS One. 2017;12:e0182089.
   PubMed Web of Science ®Google Scholar
• Lei J, Chai Y, Xiao J, et al. Antifibrotic potential of bone marrowderived mesenchymal stem cells in biliary atresia mice. Mol Med Rep. 2018;18:3983–3988.
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Giang T, et al. Mechanisms of cholangiocyte responses to injury. Biochim Biophys Acta. 2018;1864:1262–1269.
   Web of Science ®Google Scholar
• Glaser SS, Gaudio E, Miller T, et al. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med. 2009;11:e7.
   PubMed Web of Science ®Google Scholar
• Afroze S, Meng F, Jensen K, et al. The physiological roles of secretin and its receptor. Ann Transl Med. 2013;1:29.
   PubMedGoogle Scholar
• Guerrier M, Attili F, Alpini G, et al. Prolonged administration of secretin to normal rats increases biliary proliferation and secretin-induced ductal secretory activity. Hepatobiliary Surg Nutr. 2014;3:118–125.
   PubMedGoogle Scholar
• Glaser S, Meng F, Han Y, et al. Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. Gastroenterology. 2014;146:1795–1808.
   PubMed Web of Science ®Google Scholar
• Wu N, Meng F, Zhou T, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-beta1-mediated biliary senescence. Am J Pathol. 2018;188:2264–2280.
   PubMed Web of Science ®Google Scholar
• Zhou T, Wu N, Meng F, et al. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2-/- mice by diminishing senescence of cholangiocytes. Lab Invest. 2018;98:1449–1464.
   PubMed Web of Science ®Google Scholar
• Wu N, Meng F, Invernizzi P, et al. The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice. Hepatology. 2016;64:865–879.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Francis H, Venter J, et al. Secretin-stimulation of bicarbonate secretion reduces biliary damage and liver fibrosis in a model of primary biliary cholangitis (PBC). Gastroenterology. 2017;152:S1060.
   Web of Science ®Google Scholar
• Ishii M, Iwai M, Harada Y, et al. A role of mast cells for hepatic fibrosis in primary sclerosing cholangitis. Hepatol Res. 2005;31:127–131.
   PubMed Web of Science ®Google Scholar
• Hargrove L, Kennedy L, Demieville J, et al. BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice. Hepatology. 2017;65:1991–2004.
   PubMed Web of Science ®Google Scholar
• Kennedy LL, Hargrove LA, Graf AB, et al. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab Invest. 2014;94:1406–1418.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Hargrove L, Demieville J, et al. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis. Hepatology. 2018;68:1042–1056.
   PubMed Web of Science ®Google Scholar
• Francis H, Glaser S, Demorrow S, et al. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol. 2008;295:C499–C513.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Yamazaki K, Suzuki K, et al. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol. 1997;92:2245–2249.
   PubMed Web of Science ®Google Scholar
• Alpini G, Baiocchi L, Glaser S, et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology. 2002;35:1041–1052.
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799–1807.
   PubMed Web of Science ®Google Scholar
• Hatano R, Kawaguchi K, Togashi F, et al. Ursodeoxycholic acid ameliorates intrahepatic cholestasis independent of biliary bicarbonate secretion in Vil2kd/kd mice. Biol Pharm Bull. 2017;40:34–42.
   PubMed Web of Science ®Google Scholar
• Meng F, Kennedy L, Hargrove L, et al. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2-/- mice and human primary sclerosing cholangitis. Lab Invest. 2018;98:1465–1477.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290.
   PubMed Web of Science ®Google Scholar
• Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem. 2010;391:785–789.
   PubMed Web of Science ®Google Scholar
• Masyuk AI, Huang BQ, Radtke BN, et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol. 2013;304:G1013–G1024.
   PubMed Web of Science ®Google Scholar
• Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut. 2016;65:487–501.
   PubMed Web of Science ®Google Scholar
• Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010;5:e12403.
   PubMed Web of Science ®Google Scholar
• Pean N, Doignon I, Garcin I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology. 2013;58:1451–1460.
   PubMed Web of Science ®Google Scholar
• Torres J, Bao X, Iuga AC, et al. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis. 2013;19:275–282.
   PubMed Web of Science ®Google Scholar
• Baghdasaryan A, Claudel T, Gumhold J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology. 2011;54:1303–1312.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66:724–733.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67:1890–1902.
   PubMed Web of Science ®Google Scholar
• Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology. 2003;125:825–838.
   PubMed Web of Science ®Google Scholar
• Graffner H, Gillberg PG, Rikner L, et al. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43:303–310.
   PubMed Web of Science ®Google Scholar
• Baghdasaryan A, Fuchs CD, Osterreicher CH, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64:674–681.
   PubMed Web of Science ®Google Scholar
• Al-Dury S, Wahlstrom A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8:6658.
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Yuza K, Hirose Y, et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J Lipid Res. 2016;57:1636–1643.
   PubMed Web of Science ®Google Scholar
• Wang Y, Aoki H, Yang J, et al. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology. 2017;65:2005–2018.
   PubMed Web of Science ®Google Scholar
• Glaser S, Han Y, Francis H, et al. Melatonin regulation of biliary functions. Hepatobiliary Surg Nutr. 2014;3:35–43.
   PubMedGoogle Scholar
• Ohta Y, Kongo M, Kishikawa T. Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation. J Pineal Res. 2003;34:119–126.
   PubMed Web of Science ®Google Scholar
• Tahan G, Akin H, Aydogan F, et al. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats. Can J Surg. 2010;53:313–318.
   PubMed Web of Science ®Google Scholar
• Renzi A, Glaser S, Demorrow S, et al. Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. Am J Physiol Gastrointest Liver Physiol. 2011;301:G634–G643.
   PubMed Web of Science ®Google Scholar
• Turco M, Cazzagon N, Franceschet I, et al. Morning bright light treatment for sleep-wake disturbances in primary biliary cholangitis: a pilot study. Front Physiol. 2018;9:1530.
   PubMed Web of Science ®Google Scholar
• Han Y, Onori P, Meng F, et al. Prolonged exposure of cholestatic rats to complete dark inhibits biliary hyperplasia and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2014;307:G894–G904.
   PubMed Web of Science ®Google Scholar
• Glaser S, Gaudio E, Renzi A, et al. Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol. 2011;301:G297–G305.
   PubMed Web of Science ®Google Scholar
• Wan Y, Meng F, Wu N, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology. 2017;66:528–541.
   PubMed Web of Science ®Google Scholar
• Kwak KA, Cho HJ, Yang JY, et al. Current perspectives regarding stem cell-based therapy for liver cirrhosis. Can J Gastroenterol Hepatol. 2018;2018:4197857.
   PubMedGoogle Scholar
• Wang D, Zhang H, Liang J, et al. Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model. Clin Exp Med. 2011;11:25–32.
   PubMed Web of Science ®Google Scholar
• Glaser SS, Gaudio E, Rao A, et al. Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium. Lab Invest. 2009;89:456–469.
   PubMed Web of Science ®Google Scholar
• Mancinelli R, Franchitto A, Gaudio E, et al. After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes. Am J Pathol. 2010;176:1790–1800.
   PubMed Web of Science ®Google Scholar
• Mancinelli R, Franchitto A, Glaser S, et al. GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8. Hepatology. 2013;58:251–263.
   PubMed Web of Science ®Google Scholar
• McDaniel K, Meng F, Wu N, et al. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice. Hepatology. 2017;65:544–559.
   PubMed Web of Science ®Google Scholar
• Hirsova P, Ibrahim SH, Verma VK, et al. Extracellular vesicles in liver pathobiology: small particles with big impact. Hepatology. 2016;64:2219–2233.
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Glaser S, et al. Exosomes in liver pathology. J Hepatol. 2016;65:213–221.
   PubMed Web of Science ®Google Scholar
• Masyuk AI, Huang BQ, Ward CJ, et al. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol. 2010;299:G990–G999.
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Venter J, et al. The role of the secretin/secretin receptor axis in inflammatory cholangiocyte communication via extracellular vesicles. Sci Rep. 2017;7:11183.
   PubMed Web of Science ®Google Scholar
• Chaiyadet S, Sotillo J, Smout M, et al. Carcinogenic liver fluke secretes extracellular vesicles that promote cholangiocytes to adopt a tumorigenic phenotype. J Infect Dis. 2015;212:1636–1645.
   PubMed Web of Science ®Google Scholar
• McDaniel K, Huang L, Sato K, et al. The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. J Biol Chem. 2017;292:11336–11347.
   PubMed Web of Science ®Google Scholar
• McDaniel K, Wu N, Zhou T, et al. Amelioration of ductular reaction by stem cell derived extracellular vesicles in MDR2 knockout mice via let-7 microRNA. Hepatology. 2019. DOI: 10.1002/hep.30542
   PubMed Web of Science ®Google Scholar
• Sato K, Hall C, Glaser S, et al. Pathogenesis of kupffer cells in cholestatic liver injury. Am J Pathol. 2016;186:2238–2247.
   PubMed Web of Science ®Google Scholar